v3.25.4
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2025
Dec. 31, 2024
Current assets:    
Cash and cash equivalents $ 51,238 $ 41,582
Accounts receivable, net 128,303 127,393
Inventory 82,236 92,475
Prepaid and other current assets 11,065 14,160
Total current assets 272,842 275,610
Property and equipment, net 21,899 27,012
Goodwill 7,462 7,462
Intangible assets, net 368,419 404,729
Operating lease assets 5,122 6,506
Deferred tax assets 5,522 4,745
Investment and other assets 2,293 1,892
Total assets 683,559 727,956
Current liabilities:    
Accounts payable 10,928 23,690
Accrued liabilities 130,242 135,879
Current portion of long-term debt 15,000 27,339
Current portion of contingent consideration 0 19,573
Other current liabilities 4,210 3,917
Total current liabilities 160,380 210,398
Long-term debt, less current portion 278,951 308,288
Deferred income tax liabilities 433 564
Other long-term liabilities 15,348 23,102
Total liabilities 455,112 542,352
Commitments and Contingencies (Note 12)
Stockholders’ Equity:    
Additional paid-in capital 520,851 508,092
Accumulated deficit (334,929) (357,661)
Accumulated other comprehensive loss (1,900) (2,573)
Total stockholders’ equity attributable to Bioventus Inc. 184,105 147,940
Noncontrolling interest 44,342 37,664
Total stockholders’ equity 228,447 185,604
Total liabilities and stockholders’ equity 683,559 727,956
Common Class A    
Stockholders’ Equity:    
Common stock, value 67 66
Common Class B    
Stockholders’ Equity:    
Common stock, value $ 16 $ 16